Abdelwahab Heba Wagih, Abd El-Maksoud Amina
Department of Chest Medicine, Mansoura University, Mansoura, Egypt.
Clin Exp Vaccine Res. 2023 Apr;12(2):121-126. doi: 10.7774/cevr.2023.12.2.121. Epub 2023 Apr 30.
Sublingual immunotherapy is currently promoted by various companies, with administration schedules variable in the different products even though almost all are standardized immunologically. So, this study was planned to examine the efficacy of simple nondaily dosing of sublingual immunotherapy instead of the widely used daily schedule.
Fifty-two patients with allergic rhinitis and bronchial asthma were enrolled. Sublingual immunotherapy (manufactured at the allergen immunotherapy preparation unit at Mansoura University) was given in suitable bottles with a dropper mechanism that permits comfortable dosing under the tongue. The physician recommended that the patient put the drops under his/her tongue and leave the drops beneath the tongue for 2 minutes before swallowing. This was repeated every 3 days, with the drop number and concentration gradually rising.
After 2 months of follow-up, 65.8% responded partially to the symptom score and 26.3% responded completely to the medication score. There was a significant decline in the symptom and medication scores from the baseline scores (p<0.0001). After 4 months of follow-up, 95.8% responded partially to symptom scores and no one has not responded; 54.2% responded completely to medication scores; and 81% of studied patients had no side effects. However, the most frequent side effect was a sore throat.
Our nondaily schedule of sublingual immunotherapy is tolerable, safe, and effective in patients with allergic rhinitis and bronchial asthma.
目前，多种公司都在推广舌下免疫疗法，尽管几乎所有产品在免疫学上都是标准化的，但不同产品的给药方案各不相同。因此，本研究旨在检验简单的非每日给药的舌下免疫疗法而非广泛使用的每日给药方案的疗效。
招募了52例过敏性鼻炎和支气管哮喘患者。舌下免疫疗法（由曼苏拉大学变应原免疫疗法制剂单位生产）装在配有滴管装置的合适瓶子中，便于在舌下舒适给药。医生建议患者将滴剂置于舌下，吞咽前在舌下保留2分钟。每3天重复一次，滴剂数量和浓度逐渐增加。
随访2个月后，65.8%的患者症状评分部分改善，26.3%的患者药物评分完全改善。症状和药物评分较基线评分显著下降（p<0.0001）。随访4个月后，95.8%的患者症状评分部分改善，无人无改善；54.2%的患者药物评分完全改善；81%的研究患者无副作用。然而，最常见的副作用是喉咙痛。
我们的非每日给药方案的舌下免疫疗法对过敏性鼻炎和支气管哮喘患者是可耐受、安全且有效的。
